Computed tomography (CT) is the standard of care for device sizing for balloon-expandable (BE) and self-expanding (SE) transcatheter aortic valve implantation (TAVI) and has dramatically impacted outcomes in this field, particularly the frequency of paravalvular aortic regurgitation (PAR)1,2. In this issue of EuroIntervention, Kim et al describe multicentric outcomes of 198 patients treated with a novel SE transcatheter heart valve (THV) device, the Edwards CENTERA (Edwards Lifesciences, Irvine, CA, USA) in the context of CT-based oversizing, as assessed prospectively by a dedicated CT core lab3.
The Edwards CENTERA is a relatively novel THV whose first-in-man (FIM) experience was described ...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com